Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Quietly picks up...for only 20 minutes....lol
Why certainly....my money not intended for this POS
Knock your socks off...but you might want to wait until it hits .08
Even more thinner to .09
Ticker change not happening for at least another month +4 days from now.....less than .10 soon
All in due time
PPS already reflects ticker change.
If Prolanta progress were so good why has it been over 4 months since Oncolix changed the status on the clinical trials site?????? Probably going nowhere is my guess.
https://clinicaltrials.gov/ct2/archive/NCT02534922
Very good analysis...thanks for the heads up.
All buys today??? What stock are you looking at???
Thin to .10 :)
Selling will be heavy once this hits .20 and/or when ticker change is done. Struggling to make it to .15 with all the hoopla now. Everytime it goes up .01, .02, .03 it goes back down. Nothing will change that. After ticker change then what???? September, October, November...3 months with a whole lot of nothing going on so who needs to hang on until December gets here.
Very interesting as well..."Based upon our evaluation regarding the period ending June 30, 2017, the Company’s management, including its Principal Executive/Principal Financial Officer, has concluded that its disclosure controls and procedures were not effective due to the Company’s limited internal resources and lack of ability to have multiple levels of transaction review. Material weaknesses noted are lack of an audit committee, lack of a majority of outside directors on the board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; and management was dominated by two individuals during the three-month period ended June 30, 2017, without adequate compensating controls. Through the use of external consultants and the review process, management believes that the financial statements and other information presented herewith are materially correct.
The Company’s disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives. However, the Company’s management, including its Principal Executive and Principal Financial Officer, does not expect that its disclosure controls and procedures will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefit of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected."
https://www.sec.gov/Archives/edgar/data/1584137/000147793217004073/aepp_10q.htm
Very interesting and maybe not a good sign....."Our principal stockholder, GHC is considering a reorganization that may result in a change in ownership that would restrict our ability to utilize our prior accumulated tax benefits, but we do not expect such reorganization to have a significant effect on our operations."
https://www.sec.gov/Archives/edgar/data/1584137/000147793217004073/aepp_10q.htm
Then .08-.09
Good time to buy....but it will probably go down to .09 tomorrow so you might as well wait.
With all that that has happened during the last 15 days the average daily volume is only 307,039 as of the end of today, most of that selling.....no interest in this stock whatsoever.
Heavy selling
Smart money losing their asses
This is a valid point laraz5 makes:
"If AEPP ran to .20 on news of a fake merger then back down to 6 cents, why would one believe the actual fake merger would increase the price, when it takes place. The news is priced in"
Ever notice how many times the "float is locked" and the pps is then going to go up but never does???
Agree...same thought I have. Probably posters on this board that are buying and selling and who constantly pump up and magnify every little event that occurs.
Starting to think laraz is right
Don't bet on it......
Estimated Enrollment: 18
Study Start Date: February 2016
Estimated Study Completion Date: January 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Only 3 patients when they estimated 18??????
One of the first things someone should ask Redman is why they are 15 short of their estimate.
https://clinicaltrials.gov/ct2/show/NCT02534922
Maybe they'll let us know they have 4 trial patients instead of 3.
Seems like lots of folks are banking on the name change to boost the pps....don't count on it, name change is merely a formality.
"Phase I clinical trials often last several months to a year. They usually have only 10 to 30 people. Doctors offer treatment in phase I clinical trials to people whose cancers won’t respond to standard treatments. Doctors don’t design these trials to test how well a treatment or combination of treatments works. However, the treatment given during this phase sometimes may help to slow or stop the growth of a person’s cancer."
http://www.cancer.net/navigating-cancer-care/how-cancer-treated/clinical-trials/phases-clinical-trials
Only 3 patients now.
Criteria will keep the number of trial patients minimal and only 3 patients now....no way trials will meet estimated timeframes.
Estimated Study Completion Date: January 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
https://clinicaltrials.gov/ct2/show/study/NCT02534922#contacts
Criteria
Inclusion Criteria:
•Subjects must have recurrent or persistent epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. Histologic confirmation of the original primary tumor is required.
•Subjects shall have had cytoreductive (debulking) surgery.
•Formalin-fixed, paraffin-embedded tumor tissue blocks must be available for each Subject upon enrollment and provided to Sponsor within 7 days of Day 1.
•Subjects must have measurable and accessible disease.
•Subjects must either: (i) have relapsed within 6 months after (or progressed during) their last platinum regimen (this may be their primary/ adjuvant regimen); or (ii) have progressed after 2 or more prior platinum regimens (regardless of duration since most recent platinum regimen); or (iii) can not tolerate platinum therapy due to hypersensitivity or other allergic reactions.
•In addition to the first platinum-based chemotherapy, Subjects are allowed to have previously received no more than two additional cytotoxic regimens for management of recurrent or persistent disease. "Cytotoxic regimens" include any agent that targets the genetic and/or mitotic apparatus of dividing cells, resulting in dose-limiting toxicity to the bone marrow and/or gastrointestinal mucosa.
•Resolution of any effects of prior therapy (except alopecia) to NCI CTCAE v4.03 grade ≤2 and to baseline laboratory values as defined in inclusion criteria #14.
•Eastern Cooperative Oncology Group (ECOG) performance status: 0 - 2
•Life expectancy >12 weeks
•Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration. Continuation of hormone replacement therapy is permitted.
•Any prior therapy directed at the malignant tumor, including immunologic agents and chemotherapy, must be discontinued at least four weeks prior to registration (6 weeks for nitrosoureas or mitomycin C).
•Patients must have normal organ and marrow function as defined.
•Normal electrocardiogram (ECG) with corrected QT interval (QTc) ≤470 msec.
Exclusion Criteria:
•Currently receiving any other investigational agents or having participated in an investigational therapy trial within 30 days.
•Planned pregnancy, currently pregnant or breastfeeding.
•Females of childbearing potential who are not using a medically accepted means of contraception (e.g., intrauterine device, oral contraceptive, implant, Depo-Provera®, or barrier devices with spermicide) when engaging in sexual intercourse.
•History or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases or history of cerebrovascular accident, transient ischemic attack or subarachnoid hemorrhage within 6 months of registration on this study.
•Serious pre-existing medical conditions such as severe heart disease or uncontrolled: infections, hypertension, hypercalcemia, diabetes, or psychogenic disorders.
•Have any other concurrent malignancies, except adequately treated in situ carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin. (Subjects who have undergone potentially curative therapy for a prior malignancy are eligible provided there is no evidence of disease for ≥ 5 years and patient is deemed to be at low risk for recurrence.)
•Any other significant medical condition that, in the opinion of the Investigator, would significantly decrease study compliance, jeopardizes the safety of the patient, or affects the validity of the trial results.
Greenville had no dog in the fight....now they do with the merger and now have their asses covered if there is liquidation...it's all in the 8K.
Wrong!!! if the trials are going so great there would be some news other than Redman's word.
If the trials have been going great, you would think that the National Cancer Institute or Greenville Hospital would have a tidbit of information, but neither has nothing.
https://www.cancer.gov/
https://www.ghs.org/
National Cancer Institute...nothing about Prolanta https://www.cancer.gov/
Greenville Health System....nothing about Prolanta https://www.ghs.org/
The recent 8K would have certainly stated that they had completed more than 3 patient trials if there were more, but it didn't. Makes me wonder....did the trials not go well??? Is Prolanta as effective as they thought???
Ok, you caught me...already pulled the trigger awhile ago.
No, thank you for the laugh.....I laughed all the way to the bank and back :)
Ya, you're right...kinda feeling bad now about selling 500,000 shares at .18 when I bought them at .03 :)
In case you need help doing the math, that's $75,000 profit :)
See, told ya so...nows your chance to buy more!
Looks like we need another conference call :)
Makes sense to me....everyone was waiting for the Super 8K to come out to see what the real value of the company would be and now that it's out it appears the current pps reflects that.
After the ticker change let's have another conference call to talk about the ticker change!